Use of Ebola Vaccines - Worldwide, 2021-2023
Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen...
Gespeichert in:
| Veröffentlicht in: | MMWR. Morbidity and mortality weekly report 2024-04, Vol.73 (16), p.360-364 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 16 |
| container_start_page | 360 |
| container_title | MMWR. Morbidity and mortality weekly report |
| container_volume | 73 |
| creator | Kallay, Ruth Doshi, Reena H Muhoza, Pierre Choi, Mary J Legand, Anaïs Aberle-Grasse, Emma Bagayoko, Aminata Hyde, Terri B Formenty, Pierre Costa, Alejandro |
| description | Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea [Johnson & Johnson]). The Strategic Advisory Group of Experts on Immunization recommends the use of 1-dose ERVEBO during Ebola outbreaks, and in 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future Ebola outbreaks. This report describes the use of Ebola vaccines and the role of the stockpile developed and managed by the International Coordinating Group (ICG) on Vaccine Provision during 2021-2023. A total of 145,690 doses have been shipped from the ICG stockpile since 2021. However, because outbreaks since 2021 have been limited and rapidly contained, most doses (139,120; 95%) shipped from the ICG stockpile have been repurposed for preventive vaccination of high-risk groups, compared with 6,570 (5%) used for outbreak response. Repurposing doses for preventive vaccination could be prioritized in the absence of Ebola outbreaks to prevent transmission and maximize the cost-efficiency and benefits of the stockpile. |
| doi_str_mv | 10.15585/mmwr.mm7316a1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11065462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A792358387</galeid><sourcerecordid>A792358387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-554db0fec9a12c2c7def28a1553e2080d23f1dbb38751d394ca9a1992ef0f07e3</originalsourceid><addsrcrecordid>eNptkt1rHCEUxaUkNJu0r30sQwohD5mtH-OMPpUQkjYQ6EvT9k0cve5anHGrsw357-Pmi6SsgoL-zvF6OQh9IHhOOBf88zDcpPkwdIy0mrxBM8IbXouW_N5BM0waWVMi-R7az_kP3gyG36I9JtqWtozM0Ml1hiq66ryPQVc_tTF-hFzV1a-Ygr3xFk4qiimpy8LeoV2nQ4b3j_sBur44_3H2rb76_vXy7PSqNhzLqea8sT12YKQm1FDTWXBU6FIvA4oFtpQ5YvueiY4Ty2RjdCGlpOCwwx2wA_TlwXe17gewBsYp6aBWyQ863aqovXp9M_qlWsR_ihDc8qalxeHw0SHFv2vIk0qwimnKiuFGdliKVhTo-D9o8NlACHqEuL5HO9lwQmVBPz2gCx1A-dHF8q7Z4Oq0k5RxUT5TqHoLtYARSpFxBOfL8St-voUv08LgzVbB0QvBEnSYljmG9eTjmLc6mxRzTuCem0ewug-O2gRHPQWnCD6-bPkz_pQUdgdEXLn6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3049709868</pqid></control><display><type>article</type><title>Use of Ebola Vaccines - Worldwide, 2021-2023</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Kallay, Ruth ; Doshi, Reena H ; Muhoza, Pierre ; Choi, Mary J ; Legand, Anaïs ; Aberle-Grasse, Emma ; Bagayoko, Aminata ; Hyde, Terri B ; Formenty, Pierre ; Costa, Alejandro</creator><creatorcontrib>Kallay, Ruth ; Doshi, Reena H ; Muhoza, Pierre ; Choi, Mary J ; Legand, Anaïs ; Aberle-Grasse, Emma ; Bagayoko, Aminata ; Hyde, Terri B ; Formenty, Pierre ; Costa, Alejandro</creatorcontrib><description>Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea [Johnson & Johnson]). The Strategic Advisory Group of Experts on Immunization recommends the use of 1-dose ERVEBO during Ebola outbreaks, and in 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future Ebola outbreaks. This report describes the use of Ebola vaccines and the role of the stockpile developed and managed by the International Coordinating Group (ICG) on Vaccine Provision during 2021-2023. A total of 145,690 doses have been shipped from the ICG stockpile since 2021. However, because outbreaks since 2021 have been limited and rapidly contained, most doses (139,120; 95%) shipped from the ICG stockpile have been repurposed for preventive vaccination of high-risk groups, compared with 6,570 (5%) used for outbreak response. Repurposing doses for preventive vaccination could be prioritized in the absence of Ebola outbreaks to prevent transmission and maximize the cost-efficiency and benefits of the stockpile.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>DOI: 10.15585/mmwr.mm7316a1</identifier><identifier>PMID: 38662631</identifier><language>eng</language><publisher>United States: U.S. Government Printing Office</publisher><subject>Adolescent ; Adult ; Child ; Clinical trials ; Disease Outbreaks - prevention & control ; Disease prevention ; Ebola Vaccines - administration & dosage ; Ebola virus ; Ebola virus infections ; Ebolavirus ; Epidemics ; Fatalities ; FDA approval ; Full Report ; Global Health ; Hemorrhagic Fever, Ebola - epidemiology ; Hemorrhagic Fever, Ebola - prevention & control ; Humans ; Immunization ; Licenses ; Medical personnel ; Mortality ; Outbreaks ; Pharmaceutical industry ; Planning ; Prevention ; Public health ; Stockpiling ; Strategic Stockpile ; Vaccination ; Vaccines ; Viral diseases ; Virus diseases</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2024-04, Vol.73 (16), p.360-364</ispartof><rights>COPYRIGHT 2024 U.S. Government Printing Office</rights><rights>Published 2024. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c509t-554db0fec9a12c2c7def28a1553e2080d23f1dbb38751d394ca9a1992ef0f07e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065462/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11065462/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38662631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kallay, Ruth</creatorcontrib><creatorcontrib>Doshi, Reena H</creatorcontrib><creatorcontrib>Muhoza, Pierre</creatorcontrib><creatorcontrib>Choi, Mary J</creatorcontrib><creatorcontrib>Legand, Anaïs</creatorcontrib><creatorcontrib>Aberle-Grasse, Emma</creatorcontrib><creatorcontrib>Bagayoko, Aminata</creatorcontrib><creatorcontrib>Hyde, Terri B</creatorcontrib><creatorcontrib>Formenty, Pierre</creatorcontrib><creatorcontrib>Costa, Alejandro</creatorcontrib><title>Use of Ebola Vaccines - Worldwide, 2021-2023</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea [Johnson & Johnson]). The Strategic Advisory Group of Experts on Immunization recommends the use of 1-dose ERVEBO during Ebola outbreaks, and in 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future Ebola outbreaks. This report describes the use of Ebola vaccines and the role of the stockpile developed and managed by the International Coordinating Group (ICG) on Vaccine Provision during 2021-2023. A total of 145,690 doses have been shipped from the ICG stockpile since 2021. However, because outbreaks since 2021 have been limited and rapidly contained, most doses (139,120; 95%) shipped from the ICG stockpile have been repurposed for preventive vaccination of high-risk groups, compared with 6,570 (5%) used for outbreak response. Repurposing doses for preventive vaccination could be prioritized in the absence of Ebola outbreaks to prevent transmission and maximize the cost-efficiency and benefits of the stockpile.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Child</subject><subject>Clinical trials</subject><subject>Disease Outbreaks - prevention & control</subject><subject>Disease prevention</subject><subject>Ebola Vaccines - administration & dosage</subject><subject>Ebola virus</subject><subject>Ebola virus infections</subject><subject>Ebolavirus</subject><subject>Epidemics</subject><subject>Fatalities</subject><subject>FDA approval</subject><subject>Full Report</subject><subject>Global Health</subject><subject>Hemorrhagic Fever, Ebola - epidemiology</subject><subject>Hemorrhagic Fever, Ebola - prevention & control</subject><subject>Humans</subject><subject>Immunization</subject><subject>Licenses</subject><subject>Medical personnel</subject><subject>Mortality</subject><subject>Outbreaks</subject><subject>Pharmaceutical industry</subject><subject>Planning</subject><subject>Prevention</subject><subject>Public health</subject><subject>Stockpiling</subject><subject>Strategic Stockpile</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Virus diseases</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt1rHCEUxaUkNJu0r30sQwohD5mtH-OMPpUQkjYQ6EvT9k0cve5anHGrsw357-Pmi6SsgoL-zvF6OQh9IHhOOBf88zDcpPkwdIy0mrxBM8IbXouW_N5BM0waWVMi-R7az_kP3gyG36I9JtqWtozM0Ml1hiq66ryPQVc_tTF-hFzV1a-Ygr3xFk4qiimpy8LeoV2nQ4b3j_sBur44_3H2rb76_vXy7PSqNhzLqea8sT12YKQm1FDTWXBU6FIvA4oFtpQ5YvueiY4Ty2RjdCGlpOCwwx2wA_TlwXe17gewBsYp6aBWyQ863aqovXp9M_qlWsR_ihDc8qalxeHw0SHFv2vIk0qwimnKiuFGdliKVhTo-D9o8NlACHqEuL5HO9lwQmVBPz2gCx1A-dHF8q7Z4Oq0k5RxUT5TqHoLtYARSpFxBOfL8St-voUv08LgzVbB0QvBEnSYljmG9eTjmLc6mxRzTuCem0ewug-O2gRHPQWnCD6-bPkz_pQUdgdEXLn6</recordid><startdate>20240425</startdate><enddate>20240425</enddate><creator>Kallay, Ruth</creator><creator>Doshi, Reena H</creator><creator>Muhoza, Pierre</creator><creator>Choi, Mary J</creator><creator>Legand, Anaïs</creator><creator>Aberle-Grasse, Emma</creator><creator>Bagayoko, Aminata</creator><creator>Hyde, Terri B</creator><creator>Formenty, Pierre</creator><creator>Costa, Alejandro</creator><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><general>Centers for Disease Control and Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>5PM</scope></search><sort><creationdate>20240425</creationdate><title>Use of Ebola Vaccines - Worldwide, 2021-2023</title><author>Kallay, Ruth ; Doshi, Reena H ; Muhoza, Pierre ; Choi, Mary J ; Legand, Anaïs ; Aberle-Grasse, Emma ; Bagayoko, Aminata ; Hyde, Terri B ; Formenty, Pierre ; Costa, Alejandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-554db0fec9a12c2c7def28a1553e2080d23f1dbb38751d394ca9a1992ef0f07e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Child</topic><topic>Clinical trials</topic><topic>Disease Outbreaks - prevention & control</topic><topic>Disease prevention</topic><topic>Ebola Vaccines - administration & dosage</topic><topic>Ebola virus</topic><topic>Ebola virus infections</topic><topic>Ebolavirus</topic><topic>Epidemics</topic><topic>Fatalities</topic><topic>FDA approval</topic><topic>Full Report</topic><topic>Global Health</topic><topic>Hemorrhagic Fever, Ebola - epidemiology</topic><topic>Hemorrhagic Fever, Ebola - prevention & control</topic><topic>Humans</topic><topic>Immunization</topic><topic>Licenses</topic><topic>Medical personnel</topic><topic>Mortality</topic><topic>Outbreaks</topic><topic>Pharmaceutical industry</topic><topic>Planning</topic><topic>Prevention</topic><topic>Public health</topic><topic>Stockpiling</topic><topic>Strategic Stockpile</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Virus diseases</topic><toplevel>online_resources</toplevel><creatorcontrib>Kallay, Ruth</creatorcontrib><creatorcontrib>Doshi, Reena H</creatorcontrib><creatorcontrib>Muhoza, Pierre</creatorcontrib><creatorcontrib>Choi, Mary J</creatorcontrib><creatorcontrib>Legand, Anaïs</creatorcontrib><creatorcontrib>Aberle-Grasse, Emma</creatorcontrib><creatorcontrib>Bagayoko, Aminata</creatorcontrib><creatorcontrib>Hyde, Terri B</creatorcontrib><creatorcontrib>Formenty, Pierre</creatorcontrib><creatorcontrib>Costa, Alejandro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Military Database</collection><collection>Research Library</collection><collection>Social Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kallay, Ruth</au><au>Doshi, Reena H</au><au>Muhoza, Pierre</au><au>Choi, Mary J</au><au>Legand, Anaïs</au><au>Aberle-Grasse, Emma</au><au>Bagayoko, Aminata</au><au>Hyde, Terri B</au><au>Formenty, Pierre</au><au>Costa, Alejandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Ebola Vaccines - Worldwide, 2021-2023</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2024-04-25</date><risdate>2024</risdate><volume>73</volume><issue>16</issue><spage>360</spage><epage>364</epage><pages>360-364</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea [Johnson & Johnson]). The Strategic Advisory Group of Experts on Immunization recommends the use of 1-dose ERVEBO during Ebola outbreaks, and in 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future Ebola outbreaks. This report describes the use of Ebola vaccines and the role of the stockpile developed and managed by the International Coordinating Group (ICG) on Vaccine Provision during 2021-2023. A total of 145,690 doses have been shipped from the ICG stockpile since 2021. However, because outbreaks since 2021 have been limited and rapidly contained, most doses (139,120; 95%) shipped from the ICG stockpile have been repurposed for preventive vaccination of high-risk groups, compared with 6,570 (5%) used for outbreak response. Repurposing doses for preventive vaccination could be prioritized in the absence of Ebola outbreaks to prevent transmission and maximize the cost-efficiency and benefits of the stockpile.</abstract><cop>United States</cop><pub>U.S. Government Printing Office</pub><pmid>38662631</pmid><doi>10.15585/mmwr.mm7316a1</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2195 |
| ispartof | MMWR. Morbidity and mortality weekly report, 2024-04, Vol.73 (16), p.360-364 |
| issn | 0149-2195 1545-861X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11065462 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Adolescent Adult Child Clinical trials Disease Outbreaks - prevention & control Disease prevention Ebola Vaccines - administration & dosage Ebola virus Ebola virus infections Ebolavirus Epidemics Fatalities FDA approval Full Report Global Health Hemorrhagic Fever, Ebola - epidemiology Hemorrhagic Fever, Ebola - prevention & control Humans Immunization Licenses Medical personnel Mortality Outbreaks Pharmaceutical industry Planning Prevention Public health Stockpiling Strategic Stockpile Vaccination Vaccines Viral diseases Virus diseases |
| title | Use of Ebola Vaccines - Worldwide, 2021-2023 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A25%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Ebola%20Vaccines%20-%20Worldwide,%202021-2023&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Kallay,%20Ruth&rft.date=2024-04-25&rft.volume=73&rft.issue=16&rft.spage=360&rft.epage=364&rft.pages=360-364&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/10.15585/mmwr.mm7316a1&rft_dat=%3Cgale_pubme%3EA792358387%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3049709868&rft_id=info:pmid/38662631&rft_galeid=A792358387&rfr_iscdi=true |